Benestermycin, intramammaarsuspensioon veistele
Benestermycin, intramammaarsuspensioon veistele
Authorised
- Framycetin sulfate
- Benethamine penicillin
- Penethamate hydriodide
Product identification
Medicine name:
Benestermycin, intramammaarsuspensioon veistele
Active substance:
- Framycetin sulfate
- Benethamine penicillin
- Penethamate hydriodide
Target species:
-
Cattle (dry cow)
Route of administration:
-
Intramammary use
Product details
Active substance and strength:
-
Framycetin sulfate100.00/milligram(s)1.00Syringe
-
Benethamine penicillin280.00/milligram(s)1.00Syringe
-
Penethamate hydriodide100.00/milligram(s)1.00Syringe
Pharmaceutical form:
-
Intramammary suspension
Withdrawal period by route of administration:
-
Intramammary use
-
Cattle (dry cow)
-
Meat and offal8day
-
Milk36hourPiimale: 36 tundi pärast poegimist, kui ravimit manustati 35 päeva või rohkem enne poegimist. 37 päeva pärast ravi, kui ravimit manustati vähem kui 35 päeva enne poegimist.
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ51RC25
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Estonia
Available in:
-
Estonia
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Haupt Pharma Latina S.r.l.
- Lohmann Pharma Herstellung GmbH
Responsible authority:
- State Agency Of Medicines
Authorisation number:
- 1513
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Estonian (PDF)
Published on: 19/06/2024